ihv01

Vaccineexperimental

Clinical trial activity

4 trials · 14 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Nov 1, 2015 (NCT02756208)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • ihv01

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04658667Phase 1Aug 31, 2021Government of Thailand, Mahidol University, United States Army
NCT04041674Phase 1Sep 30, 2019Duke University, GeoVax, Inc., National Institute of Allergy and Infectious Diseases (NIAID), University of Maryland, University of Rochester, University of Washington, Vanderbilt University
NCT03505060Phase 1Jan 1, 2019City of San Francisco, National Institute of Allergy and Infectious Diseases (NIAID), University of Alabama, Birmingham
NCT02756208Phase 1Nov 1, 2015Bill and Melinda Gates Foundation, Profectus BioSciences, Inc., University of Maryland
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (14)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institute of Allergy and Infectious Diseases (NIAID)Government2212019
University of MarylandAcademic/Hospital2112015
Bill and Melinda Gates FoundationAcademic/Hospital1012015
City of San FranciscoGovernment1012019
Duke UniversityAcademic/Hospital1012019
GeoVax, Inc.For profit1012019
Government of ThailandGovernment1012021
Mahidol UniversityAcademic/Hospital1012021
Profectus BioSciences, Inc.For profit1012015
United States ArmyGovernment1112021
University of Alabama, BirminghamAcademic/Hospital1012019
University of RochesterAcademic/Hospital1012019
University of WashingtonAcademic/Hospital1012019
Vanderbilt UniversityAcademic/Hospital1012019
14 organizations
Page 1 / 1